Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038179 · ClinicalTrials.gov registry record · Phase 2
Center of Research Translation (CORT) Project 2
A Phase 2 study of Prehypertension and JNC 7 Stage I Hypertension, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 1
- Study location
NCT02038179: Completed Phase 2 study of Prehypertension and JNC 7 Stage I Hypertension, sponsored by University of Alabama at Birmingham.
NCT02038179 is a Phase 2 study of Prehypertension and JNC 7 Stage I Hypertension that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 99 participants, below the 567-participant average among 13 other Prehypertension trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02038179, a Phase 2 study of Prehypertension and JNC 7 Stage I Hypertension, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
We propose a novel intervention for reducing BP that could have a preferential impact in patients with hyperuricemia and gout. There is a great need for new anti-hypertensives, particularly among those with gout. The proposed study is novel in its plans to investigate the physiologic mechanisms through which urate contributes to vascular disease and by which ULT may contribute to BP reduction. Also innovative, we will: 1) determine to what extent the described benefit of lowering serum urate extends beyond the adolescent population previously studied into young adults, 2) test whether a urate-lowering approach will benefit individuals that do not yet meet the current definition of hyperuricemia and do not have gout, and 3) begin to explore potential mechanisms for the higher prevalence of hypertension among African-Americans. If successful, this work could translate to the standard of clinical care and to health care recommendations for the population as a whole.
Primary Outcome
Compare systolic blood pressure (SBP) captured by wearing a 24 hour ambulatory blood pressure monitor during each phase of treatment (allopurinol 300 mg/day PO or placebo). Change in systolic blood pressure is calculated by comparing SBP at the end of each treatment phase to pre-treatment values.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Allopurinol
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
What the finished NCT02038179 record still lists
NCT02038179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 567-participant average among 13 other Prehypertension trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Prehypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02038179 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT02038179 about?
NCT02038179 is a clinical study titled "Center of Research Translation (CORT) Project 2". We propose a novel intervention for reducing BP that could have a preferential impact in patients with hyperuricemia and gout. There is a great need for new anti-hypertensives, particularly among those with gout. The proposed study is novel in its plans to investigate the physiologic mechanisms thro...
What is the current status of trial NCT02038179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2014-07. Estimated completion is 2018-08.
What conditions does trial NCT02038179 study?
This clinical trial studies the following conditions: Prehypertension, JNC 7 Stage I Hypertension.
What interventions are being tested in trial NCT02038179?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG).
Who is sponsoring clinical trial NCT02038179?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02038179 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prehypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02038179's enrollment target sits among peer trials
99 7th of 13 higher than 7 of 13 other Prehypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prehypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Community Park-Based Programs for Health Promotion: The Fit2Lead Prospective Cohort Study
RECRUITING
-
Sympathetic Overactivity in Post-traumatic Stress Disorder
RECRUITING · NA
-
Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study
RECRUITING
-
Impact of Sex in the Effect of Dietary Capsaicin on Cardiovascular Health
RECRUITING · NA
-
Equity in Prevention and Progression of Hypertension by Addressing Barriers to Nutrition and Physical activitY
ACTIVE NOT RECRUITING · NA
-
HELP-HY: Health Education and sLeep Program in HYpertension
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia